Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: J Heart Lung Transplant. 2017 Sep 1;37(3):376–384. doi: 10.1016/j.healun.2017.08.011

Figure 3.

Figure 3

Elevated levels of IL-6 are associated with worse RV function in PAH. Patients with higher levels of IL-6 have significantly reduced RVFAC (23 ± 12% vs 38 ± 11%, p = 0.0004) (A), lower TAPSE (1.3 ± 0.3 cm vs 2.1 ± 0.5 cm, p < 0.0001) (B) and worse RV-PA coupling, as defined by RVFAC/mPAP (0.6 ± 0.5%/mm Hg vs 0.9 ± 0.5%/mm Hg, p = 0.03) (C) and TAPSE/mPAP (0.3 ± 0.1 mm/mm Hg vs 0.5 ± 0.3 mm/mm Hg, p = 0.003) (D) when compared to patients with lower IL-6 levels. High IL-6 is associated with higher RA pressure (13 ± 7 mm Hg vs 9 ± 5 mm Hg, p = 0.04) (E), lower cardiac index (2.0 ± 0.5 liters/min/m2 vs 2.8 ± 1.0 liters/min/m2, p = 0.002) (F) and lower stroke volume (48 ± 20 ml vs 70 ± 28 ml, p = 0.009) (G). *p < 0.05, as determined by Student’s t-test or Mann–Whitney U-test.